Table 2. Summary of Guideline Key Action Statements (KAS)
(cont'd)
Statement Action Strength
7. Oral Antihistamines Clinicians should recommend oral second-
generation/less sedating antihistamines for
patients with AR and primary complaints of
sneezing and itching.
S-A
8. Intranasal
Antihistamines
Clinicians may offer INAs for patients with
seasonal, perennial, or episodic AR.
O-A
9. Oral Leukotriene
Receptor Antagonists
(LTRAs)
Clinicians should NOT offer oral LTRAs as
primary therapy for patients with AR.
R-A
(against)
10. Combination Therapy Clinicians may offer combination
pharmacologic therapy for patients with
AR who have inadequate response to
pharmacologic monotherapy.
O-A
11. Immunotherapy Clinicians should offer, or refer to a clinician
who can offer, immunotherapy (sublingual
or subcutaneous) for patients with AR who
have inadequate response to symptoms with
pharmacologic therapy with or without
environmental controls.
R-A
12. Inferior Turbinate
Reduction
Clinicians may offer, or refer to a surgeon
who can offer, inferior turbinate reduction
for patients with AR with nasal airway
obstruction and enlarged inferior turbinates
who have failed medical management.
O-C
13. Acupuncture Clinicians may offer, or refer to a clinician
who can offer, acupuncture for patients with
AR who are interested in nonpharmacologic
therapy.
O-B
14. Herbal Therapy No recommendation regarding the use of
herbal therapy for patients with AR.
NR
3
